Ki67 does not predict recurrence for low-grade appendiceal mucinous neoplasms with peritoneal dissemination after cytoreductive surgery and HIPEC.

Low-grade appendiceal mucinous neoplasms (LAMN) can disseminate to become low-grade mucinous carcinoma peritonei (LGMCP), which is optimally treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC). Approximately half of the patients with LGMCP recur despite complete cytoreduction, and risk factors for recurrence are poorly understood. We sought to evaluate if Ki67 predicts progression of LGMCP after CRS/HIPEC. A retrospective review of a prospectively maintained database was performed to identify patients treated with complete CRS/HIPEC for LGMCP from 2008 to 2019 with Ki67 assessed. Patient characteristics, histologic data, average and focally high "hotspot") Ki67 index, progression-free survival (PFS), and overall survival (OS) were analyzed. Ki-67 immunostain was performed on the histologic section with the highest cellularity and architectural complexity. Forty-four patients with LGMCP (55% male, median age 61) were identified. The median Ki67 score and hotspot Ki67 score was 15% (1-70) and 50% (1-90), respectively. On univariate analysis, average Ki67 and hotspot Ki67 were not predictive of PFS when analyzed as continuous normalized values (HR 1.0, p = 0.79 and HR 1.1, p = 0.38, respectively) or as categorical values when stratified by the median (HR 0.9, p = 0.67 and HR 1.0, p = 0.93). This remained true on multivariate analysis when stratified for peritoneal cancer index, CEA, and completeness of cytoreduction score for both normalized Ki67 and hotspot Ki67 (HR 0.9 [95% CI 0.8-1.3], p = 0.94 and HR 1.04 [95% CI 0.8-1.3], p = 0.73, respectively). Ki67 failed to predict disease recurrence for patients with LGMCP in this cohort.

Careful Patient Selection Achieves High Radiocephalic Arteriovenous Fistula Patency in Diabetic and Female Patients.

BACKGROUND: The radiocephalic arteriovenous fistula (rcAVF) is considered the first-choice site for hemodialysis access; however, it has been associated with decreased rates of patency and maturation in women and diabetic patients in some studies. We hypothesized that careful preoperative selection of patients for an rcAVF fistula would result in a high 1-year patency rate and that external factors, such as female gender and diabetes mellitus (DM), would not adversely affect fistula patency. METHODS: This is a retrospective study of all patients who underwent rcAVF creation at a single institution from January 2011 to June 2016. Patients were carefully selected based on clinical examination and preoperative, B-mode, ultrasound findings. Primary patency and primary assisted patency at 1 year were calculated. Survival analysis was also conducted to evaluate for factors associated with rcAVF patency. RESULTS: There were 158 patients identified who underwent rcAVF fistula creation and were seen in follow-up. The 1-year primary and primary assisted patency rates were 62% and 81%, respectively. On Kaplan-Meier survival analysis, there was no difference in rcAVF patency with respect to gender, Hispanic race, anesthesia type, DM, and smoking status. Patients with a prior AVF, most often received in the nondominant arm and now receiving an rcAVF in the dominant arm, had a significantly higher risk of fistula failure, in both primary and primary assisted patency survival (hazard ratio 5.1, 95% confidence interval 1.6-16.2, P = 0.06). Patients without a history of hypertension (HTN), as noted in the electronic medical records, trended toward a higher risk of primary assisted patency rcAVF failure, compared to those who had a history of HTN (hazard ratio 3.0, 95% confidence interval 1.1-7.9, P = 0.03). CONCLUSIONS: With careful patient selection, the rcAVF can achieve a high 1-year primary assisted patency rate. Female gender and DM were not significantly associated with an increase in rcAVF failure and should not be heavily relied on in-patient selection. First-time AVF patients and patients with a history of HTN may be associated with increased rcAVF patency.